Pain Clinics International

Pain Clinics International Inc

• Company Website: www.painclinicsint.com
• Head Office Address: 103-3606 Aldercrest Drive, North Vancouver, BC, Ca
• Company Phone No: 604-862-3439
• Company Email Address: dr.terry@painclinicsint.com

Business

Pain Clinics International (“PCI”) is federally incorporated in Canada. The Company is focused on the importation of bulk medical cannabis products from Canada into Germany for the treatment of chronic pain and to reduce the use of opioid pain medications. Cannabidiol (CBD) is one of the main active ingredients in medical cannabis. CBD faces fewer export and import regulations if the content of Tetrahydrocannabinol (THC), the main psychotropic ingredient in cannabis, is less than 0.3%. We will pursue the required approvals to import THC containing products as sales of CBD products are generated. CDB is an effective treatment for chronic pain and mitigates the effects of opioid withdrawal. THC can help patients to sleep more soundly which is very important requirement for pain management. Medical cannabis has no harmful side effects when used as directed by medical professionals.

Market

In Germany, direct medical costs for chronic pain are over €4.1 Billion annually. The 24 Million patients who suffer from chronic pain have access to 3,300 physicians who specialize in pain management. The market for CBD products alone in Germany is estimated to be 75 Million Euros annually.

Market drivers

The market is growing with aging populations. Governments are increasing their focus on chronic pain and, along with doctors, patients and funding agencies, are seeking alternatives to opioids and other prescription medications. The misguided war on drugs is abating and the benefits of medical cannabis are now being recognized.

Business strategy

Germany will import cannabis products because, as of December, 2017, no legal domestic production was established. The importation and packaging of bulk cannabis products containing less than 0.3% THC faces few regulatory hurdles and attractive margins are achievable. We will also work toward the registration required for the importation and distribution of cannabis products containing medicinal THC levels.

Sales & marketing strategy

The initial sales targets will be online sales to the general public and to the professionals who provide pain management services, including physicians, nurses, psychologists, occupational therapists, pharmacists, physiotherapists, dieticians and chiropractors. We are currently working with a pain management clinic in Cologne, Germany, that will support a pilot project using CBD and can be used as a model for sales to other clinics. Results obtained from the clinics that are customers will be used to market the benefits of CBD to chronic pain patients through an online store.

All Team Members & Relevant Parties

---

Terrance George Owen

• Position at Issuer: President, Director & Secretary
• Municipality of Residence: North Vancouver, BC
• Email Address: dr.terry@painclinicsint.com
• Principal Occupation for the Last Five Years: CEO & a Director of Cell MedX (OTCQB:CMXC) from December, 2017 to present . Director of Champion Pain Care Corporation (OTCBB:CPAI) from 2013 to 2017, CEO from 2013 to 2015 and CFO from 2016 to 2017. President, CEO & a Director of ALDA Pharmaceuticals Corp. (Since renamed Vanc Pharmaceuticals Inc., TSX-V:VANC), 2000 to 2013

• About:

  1968, BSc (Honours), Biology, University of Victoria. 1970, MSc, Biology, University of New Brunswick. 1974, PhD, Zoology, University of British Columbia. 1991, MBA, Simon Fraser University.

  2000 to 2013, President, CEO & Director, ALDA Pharmaceuticals Corp., an infection control company, (Now Vanc Pharmaceuticals Inc. – VANC:TSX-V). 1980 to 2002, President of Helix Biotech ULC, medical products, biotech R&D & DNA identity testing services. 1995 to 1998, President & Director, Helix BioPharma Corp. (HBP:TSE), a generic pharmaceutical company. Co-founder, Champion Pain Care Corporation (CPAI:OTCBB), CEO, 2013 to 2015; Director, 2013 to 2017; CFO, 2016 to 2017. December, 2017 to present, CEO & Director, Cell MedX Corp. (CMXC:OTCQB), a medical device company. Director & Audit Committee member of a number of public companies listed on the TSX Venture Exchange since 2002.

  Corporate expertise - Startups to exit strategies and everything in between.

  Technical expertise – Biosciences, medical products and R&D.

---

Patricia Elaine Genereaux

• Position at Issuer: Control Person
• Municipality of Residence: North Vancouver, BC
• Email Address: N/A
• Principal Occupation for the Last Five Years: Self Employed

• About:

  As a successful, self-employed entrepreneur for many years in the design, decorating and construction markets, Ms. Genereaux has dealt with all aspects of business administration including sales & marketing, customer service, finance and managing receivables & payables, tax administration at all levels of government, contractors and employees.